company background image
1783 logo

Maxigen Biotech TWSE:1783 Stock Report

Last Price

NT$45.55

Market Cap

NT$4.1b

7D

1.4%

1Y

-20.4%

Updated

24 Jul, 2024

Data

Company Financials

1783 Stock Overview

Researches, develops, produces, and sells implantable medical device and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally.

1783 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends3/6

Maxigen Biotech Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Maxigen Biotech
Historical stock prices
Current Share PriceNT$45.55
52 Week HighNT$64.29
52 Week LowNT$41.80
Beta0.91
11 Month Change-1.09%
3 Month Change7.18%
1 Year Change-20.42%
33 Year Change5.96%
5 Year Change108.77%
Change since IPO4.59%

Recent News & Updates

Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Mar 28
Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Recent updates

Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Mar 28
Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

Apr 22
Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Apr 01
We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 16
Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Feb 23
The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Feb 02
Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Jan 10
Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

Dec 14
Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Nov 22
If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Shareholder Returns

1783TW BiotechsTW Market
7D1.4%1.4%-4.6%
1Y-20.4%9.9%31.4%

Return vs Industry: 1783 underperformed the TW Biotechs industry which returned 9.9% over the past year.

Return vs Market: 1783 underperformed the TW Market which returned 31.4% over the past year.

Price Volatility

Is 1783's price volatile compared to industry and market?
1783 volatility
1783 Average Weekly Movement4.8%
Biotechs Industry Average Movement5.5%
Market Average Movement4.7%
10% most volatile stocks in TW Market8.6%
10% least volatile stocks in TW Market2.2%

Stable Share Price: 1783 has not had significant price volatility in the past 3 months.

Volatility Over Time: 1783's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998n/aChing-Ting Chenmbi-bio.com

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical device and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates in two segments, Biomedical Products and Consumer Products. The company offers intra-articular injections under the ArtiAid, ArtiAid Plus, and ArtiBest names to treat osteoarthritis; Foramic, a bone substitute granule; FormaGraft, a bone graft substitute; GingivAid, a collagen dental grafts for use in dental implant surgery; and BestAid, a collagen bone graft.

Maxigen Biotech Inc. Fundamentals Summary

How do Maxigen Biotech's earnings and revenue compare to its market cap?
1783 fundamental statistics
Market capNT$4.05b
Earnings (TTM)NT$149.80m
Revenue (TTM)NT$606.15m

27.1x

P/E Ratio

6.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1783 income statement (TTM)
RevenueNT$606.15m
Cost of RevenueNT$191.00m
Gross ProfitNT$415.15m
Other ExpensesNT$265.36m
EarningsNT$149.80m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 29, 2024

Earnings per share (EPS)1.68
Gross Margin68.49%
Net Profit Margin24.71%
Debt/Equity Ratio0%

How did 1783 perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

59%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.